Background
Sepsis as a dysregulated host response to infection
Platelets: multifunctional tiny cytoplasmic fragments
Platelets as key players in the inflammatory reaction; critical links with coagulation
Platelets in vascular and tissue integrity
Platelets contribute to the innate immune response against infection
Platelets in MOD pathophysiology
Endothelium in MOD: a common pathophysiological denominator
Platelets in acute lung injury (ALI) in sepsis
Platelets and acute kidney injury (AKI) in sepsis
Platelets and organ-to-organ crosstalk in sepsis
Platelet count in sepsis and the dilemma of platelet transfusion
Platelet count and dynamics of platelet count as determinants of clinical outcome in sepsis patients
The multiple causes of thrombocytopenia in sepsis patients
Can platelets represent therapeutic targets and diagnostic tools in sepsis?
Authors | Study year | Study type and setting | Patient number | Antiplatelet agent | Patients | Study conclusions | Potential limitations |
---|---|---|---|---|---|---|---|
Wang et al. [268] | 2016 | Meta analysis of cohort studies | 14,612 | ASA, clopidogrel, ticlopidine | ICU patients with ARDS predisposing conditions | Reduced mortality and lower incidence of ARDS | Non-sepsis patients included Treatment bias of antiplatelet agents |
Kor et al. [269] | 2012–2014 | Multicenter, double-blind, placebo-controlled, randomized clinical trial | 390 | ASA | Patients with elevated risk for developing ARDS in the emergency department | ASA did not reduce the risk of ARDS and 28-day or 1-year survival | Non-sepsis patients included Low rate of ARDS development |
Wiewel et al. [260] | 2011–2014 | Prospective observational study with propensity matching | 972 | Mostly ASA | Sepsis within 24 h after admission in 2 mixed medical/surgical ICU | Antiplatelet therapy was not associated with alterations in the presentation or outcome of sepsis or the host response | Treatment bias of ASA Inadequate patient number and power |
Osthoff et al. [270] | 2001–2013 | Retrospective cohort study with propensity matching | 689 | ASA | Patients with S. aureus and E. coli bloodstream infection admitted in a single medical/surgical ICU | Low-dose ASA at the time of bloodstream infection was strongly associated with a reduced short-term mortality in patients with S. aureus bloodstream infection | Treatment bias of ASA at the time of enrolment Severity at presentation was not included in the analysis model Inadequate patient number and power |
Tsai et al. [255] | 2000–2010 | A nation-wide population-based cohort and nested case–control study | 683,421 | ASA, clopidogrel, ticlopidine | Sepsis | Antiplatelet agents were associated with a survival benefit in sepsis patients | Claims database |
Chen et al. [253] | 2006–2012 | Secondary analysis of prospective cohort with propensity matching | 1149 | ASA | Patients admitted in a mixed ICU for at least 2 days | Decreased risk of ARDS | Non-sepsis patients included Treatment bias of ASA |
Boyle et al. [271] | 2010–2012 | Prospective observational study | 202 | ASA | ICU patients requiring invasive mechanical ventilation | Reduced risk of ICU mortality | Treatment bias of ASA Non-sepsis patients included |
Valerio-Rojas et al. [249] | 2007–2009 | Retrospective cohort with propensity matching | 651 | ASA, clopidogrel | ICU patients with sepsis | No decrease in hospital mortality but decreased incidence of ARDS | Inadequate patient number and power Unmeasured bias and confounding |
Otto et al. [251] | 2013 | Retrospective cohort | 886 | ASA, clopidogrel | Surgical ICU patients with sepsis and a minimum length of stay of 48 h and a history of atherosclerotic vascular diseases | ASA treatment reduced the ICU and hospital mortality. Combination of ASA with clopidogrel did not show any significant effect on mortality. Clopidogrel alone might have a similar benefit | Unmeasured bias and confounding |
Sossdorf et al. [250] | 2013 | Retrospective cohort | 979 | ASA | Septic patients admitted to a surgical ICU | Decreased mortality with ASA or NSAIDs was associated with decreased hospital mortality. No benefit when ASA and NSAIDs are given together | Unmeasured bias and confounding |
Eisen et al. [248] | 2000–2009 | Retrospective cohort study with propensity matching | 7945 | ASA | ICU patients with SIRS/sepsis on ASA at the time of SIRS/sepsis | ASA was associated with survival | Treatment bias of ASA at the time of enrolment and confounders |
O’Neal et al. [272] | 2006–2008 | Cross-sectional analysis of a prospective cohort | 575 | ASA and Statin | Patients admitted in a mixed ICU for at least 2 days | ASA was not associated with the diagnosis of ALI/ARDS, sepsis or hospital mortality | Treatment bias of ASA Unmeasured bias and confounding Non-sepsis patients included |
Erlich et al. [246] | 2006 | Retrospective cohort | 161 | ASA, clopidogrel, ticlopidine | Adult patients admitted in a medical ICU with a major risk factor for ALI | Reduced incidence of ALI/ARDS | Treatment bias of ASA Non-sepsis patients included |
Kor et al. [256] | 2009 | Second analysis of prospective multicenter observational study | 3855 | ASA | Consecutive, adult, non-surgical patients with at least one major risk factor for ALI | ASA was not associated with ICU or hospital mortality and ICU or hospital lengths | Treatment bias of ASA Non-sepsis patients included Unmeasured bias and confounding |
Storey et al. [273] | 2006–2008 | Post hoc analysis PLATO study | 18,421 | Ticagrelor vs clopidogrel | Patients with acute coronary syndrome | Reduced mortality following pulmonary infection and sepsis in acute coronary syndrome with ticagrelor | Unmeasured bias and confounding |
Winning et al. [245] | 2007–2009 | Retrospective cohort | 615 | ASA, clopidogrel | Consecutive patients admitted in a mixed ICU | Reduction in organ failure and mortality in critically ill patients with pre-existing medication | Non-sepsis patients included Treatment bias of ASA |
Winning et al. [274] | 2002–2007 | Retrospective cohort | 224 | ASA, clopidogrel ticlopidine | Patients admitted for CAP not receiving statins and using antiplatelet drugs for more than 6 months | Reduction in need of intensive care treatment and length of hospital stay | Unmeasured bias and confounding |
Gross et al. [275] | 2001–2005 | Retrospective cohort | 417,648 | Clopidogrel | All adult (≥ 18 years) Medicaid beneficiaries in Kentucky | Increased CAP incidence and no significant reduction in severity | Claims database |